Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | QUAZAR AML-001: oral azacitidine as maintenance therapy in AML

Farhad Ravandi • 9 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Azacitidine
QUAZAR AML-001

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of QUAZAR AML-001 (NCT01757535) which aimed to determine the efficacy of oral azacitidine plus best supportive care as maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Farhad Ravandi

1:23
The value of MRD as a marker for disease eradication in AML
Farhad Ravandi • 8 Dec 2023
1:31
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi • 8 Dec 2023
1:29
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi • 8 Dec 2023
1:43
Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL
Farhad Ravandi • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals